( LSE:SHP,NASDAQ-NMS:SHPG,Bloomberg:SHP@LN,Bloomberg:SHPGF@US,RICS:SHP.L,RICS:SHPGY.O )

News from Shire plc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Feb 24, 2017, 07:17 ET CHMP Recommends EU Conditional Marketing Authorisation for Natpar® (Parathyroid Hormone) for Patients with Chronic Hypoparathyroidism

This Press Release is intended for Global Use If approved, Natpar would be the first licensed recombinant parathyroid hormone in Europe for the...


Feb 23, 2017, 04:11 ET New England Journal of Medicine Publishes Phase 1b Results for Shire's Investigational Treatment for Hereditary Angioedema, a Rare Genetic Disease

Results Served as Basis for Ongoing Phase 3 Trial Shire plc (LSE: SHP, NASDAQ: SHPG), the global leader in rare diseases, today announced the...


Feb 23, 2017, 02:00 ET Shire Launches 'Rare Count' Campaign to Personalize the Global Impact of Rare Diseases

- For Every 'Count', Shire Will Donate to Leading Rare Disease Organizations - Campaign Honoring Rare Disease Day Open to All at...


Feb 16, 2017, 07:52 ET Shire Reports Full Year 2016 Results With Record Revenue; Positioned for Continued Strong Growth Driven by Best-in-class Rare Disease Pipeline

Key growth contributions from all therapeutic areas Baxalta integration progressing ahead of schedule; Shire now the world leader in rare...


Feb 14, 2017, 07:30 ET Shire to Highlight Advancements in Rare Genetic Diseases

14 presentations and 5 satellite symposia across 3 lysosomal storage disorders at important scientific meeting represent Shire's continued focus...


Feb 07, 2017, 15:42 ET Shire Responds to U.S. Federal Trade Commission Civil Action

Shire plc (Shire) (LSE: SHP, NASDAQ: SHPG) acknowledges the decision announced today by the U.S. Federal Trade Commission ("FTC") to file a civil...


Feb 01, 2017, 13:39 ET New Data From Shire Aim to Help Close the Diagnosis and Treatment Gap for People With Hemophilia

Shire plc (LSE: SHP, NASDAQ: SHPG), the leading biotechnology company focused on serving individuals with rare diseases, presented its new...


Jan 19, 2017, 07:00 ET U.S. FDA Acknowledges Receipt of Shire's New Drug Application for SHP465 for ADHD

Shire plc (LSE: SHP, NASDAQ: SHPG) announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the Class 2 resubmission...


Jan 04, 2017, 09:30 ET Shire to Present at the 35th Annual J.P. Morgan Healthcare Conference

Shire plc (LSE: SHP, NASDAQ: SHPG) announces that Flemming Ornskov, MD, Chief Executive Officer, will present at the 35th Annual J.P. Morgan...


Dec 27, 2016, 07:00 ET Shire Announces FDA Approval of Adynovate® [Antihemophilic Factor (Recombinant), Pegylated] for use in Children and Surgical Settings

New FDA-approved indications for ADYNOVATE provides more hemophilia A patients access to proven prophylaxis with a simple, twice-weekly dosing...


Dec 02, 2016, 17:21 ET Shire Reports on Four Decades of Real-World Safety Experience With FEIBA® [Anti-Inhibitor Coagulant Complex]

Shire plc (LSE: SHP; NASDAQ: SHPG), the leading biotechnology company focused on serving individuals with rare diseases, is presenting an update...


Nov 22, 2016, 07:00 ET Shire to Establish Rare Disease Innovation Hub in Cambridge, Mass.

Shire plc (LSE: SHP, NASDAQ: SHPG) announced today that it will expand its operations in Cambridge, Massachusetts, establishing a rare disease...


Nov 16, 2016, 07:00 ET Shire Launches CUVITRU[TM] [Immune Globulin Subcutaneous (Human), 20% Solution] in the U.S. for Primary Immunodeficiency

CUVITRU, now available in the U.S., expands Shire's immunoglobulin portfolio of treatment options to meet the unique needs of children and adults...


Nov 12, 2016, 07:00 ET Tolerability Data for Shire's CUVITRU Accepted for Oral Presentation at the American College Of Allergy, Asthma & Immunology Annual Meeting

Data reveals key findings on the tolerability of CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] for patients, regardless of...


Nov 10, 2016, 07:00 ET Shire's Investor Day Showcases Strength of Rare Disease Pipeline and Commercial Portfolio

Shire plc (LSE: SHP, NASDAQ: SHPG) today will host an Investor Day focused on its commercial portfolio and innovative R&D pipeline, including...


Nov 04, 2016, 11:00 ET Broad Range of Research to be Presented at ASH 2016 Demonstrates Shire's Commitment to Addressing Unmet Needs for Patients with Rare Hematologic and Specialty Conditions

16 presentations to highlight innovation in hematology, oncology and genetic diseases Shire plc (LSE: SHP, NASDAQ: SHPG), the leading global...


Nov 04, 2016, 07:00 ET Shire to Highlight Focus on Rare Disease Innovation at Investor Day

Company to discuss strength of its commercial portfolio and robust pipeline in rare diseases and specialized conditions Hematology and Immunology...


Nov 01, 2016, 08:37 ET Shire Reports Q3 2016 Results with Record Revenues and Reiterates Full Year Non GAAP Guidance

Very strong U.S. launch for XIIDRA; marks outstanding entry into ophthalmics Baxalta integration progressing well with synergy initiatives ahead...


Oct 27, 2016, 07:00 ET Results from Shire's Phase 2 Study of Maribavir Showed Activity Against CMV Infection in Patients Undergoing Transplant

Shire plc (LSE: SHP, NASDAQ: SHPG) today presented data from a Phase 2 study evaluating maribavir (SHP620), an investigational antiviral agent...


Oct 18, 2016, 02:00 ET Shire Granted EU Marketing Authorization of Onivyde®, in Combination With 5-Fluorouracil (5-FU) and Leucovorin (LV),for the Treatment of Metastatic Adenocarcinoma of the Pancreas in Adult Patients Who Have Progressed Following Gemcitabine-Based Therapy

ONIVYDE, in combination with 5-fluorouracil (5-FU) and leucovorin (LV), is the first and only treatment approved for this patient population based...


Oct 17, 2016, 08:05 ET Multimedia Assets Available: Modern Technology and a Multi-Screen Lifestyle Viewed as Important Factors in Rising Prevalence of Dry Eye Disease

Shire plc (LSE: SHP, NASDAQ: SHPG) announces that in results released today from a new national survey, nearly nine in 10 eye care professionals...


Oct 17, 2016, 08:00 ET Modern Technology and a Multi-Screen Lifestyle Viewed as Important Factors in Rising Prevalence of Dry Eye Disease

- Results from the National Eye C.A.R.E. Survey reinforce potential link between tech-dependency and growing risk of dry eye disease...


Oct 17, 2016, 07:00 ET Shire Announces Update to Vyvanse® (lisdexamfetamine dimesylate) U.S. Labeling to Include New Longer-Term Maintenance of Efficacy Data in Adults with Moderate to Severe Binge Eating Disorder

Labeling Update Based on Maintenance of Efficacy Data from a 38-Week Phase 3 Study For U.S. Audiences Only - Shire plc (LSE: SHP, NASDAQ: SHPG)...


Oct 05, 2016, 18:07 ET Patent Trial and Appeal Board Upholds the Validity of LIALDA® Patent

Shire plc (LSE: SHP, NASDAQ: SHPG) announced today that the U.S. Patent & Trademark Office's Patent Trial and Appeal Board (PTAB) has issued...


Sep 23, 2016, 07:00 ET Shire to Showcase Continued Innovation and Leadership in Immune Deficiencies During European Society for Immunodeficiencies Biennial Meeting

Shire plc (LSE: SHP, NASDAQ: SHPG) will showcase data across its global leading immunoglobulin (IG) portfolio during the 17th Biennial Meeting of...